LMO1 intracellular antibody fragments for delivery in improved treatment of childhood neuroblastoma

Funder	Medical Research Council
Recipient Organization	Institute of Cancer Research
Country	United Kingdom
Start Date	Oct 06, 2024
End Date	Oct 05, 2028
Duration	1,460 days
Number of Grantees	2
Roles	Student; Supervisor
Data Source	UKRI Gateway to Research
Grant ID	`2933515`

Grant Description

The LIM-only protein LMO1 is implicated in neuroblastoma by synergising with MYCN to promote tumour development and metastasis.

The proposed work will use technologies we developed to isolate an inhibitory intracellular antibody and, in turn Antibody-derived (Abd) compounds, for the LMO1 paralogue LMO2.

The anti-LMO1 intracellular antibody will be used in mouse models of neuroblastoma for studies of cooperative oncogenicity with MYCN, in parallel with compound library screening for LMO1-binding Abd compounds. The reagents and compounds will have a major impact on neuroblastoma treatment.